Discovery of Taurocholic Acid Sodium Hydrate as a Novel Repurposing Drug for Intervertebral Disc Degeneration by Targeting MAPK3

Abstract

Objective:: Nowadays, more than 90% of people over 50 years suffer from intervertebral disc degeneration (IDD), but there are exist no ideal drugs. The aim of this study is to identify a new drug for IDD.

Methods:: An approved small molecular drug library including 2040 small molecular compounds was used here. We found that taurocholic acid sodium hydrate (NAT) could induce chondrogenesis and osteogenesis in mesenchymal stem cells (MSCs). Then, an in vivo mouse model of IDD was established and the coccygeal discs transcriptome analysis and surface plasmon resonance analysis (SPR) integrated with liquid chromatography–tandem mass spectrometry assay (LC-MS) were performed in this study to study the therapy effect and target proteins of NAT for IDD. Micro-CT was used to evaluate the cancellous bone. The expression of osteogenic (OCN, RNX2), chondrogenic (COL2A1, SOX9), and the target related (ERK1/2, p-ERK1/2) proteins were detected. The alkaline phosphatase staining was performed to estimate osteogenic differentiation. Blood routine and blood biochemistry indexes were analyzed for the safety of NAT.

Results:: The results showed that NAT could induce chondrogenesis and osteogenesis in MSCs. Further experiments confirmed NAT could ameliorate the secondary osteoporosis and delay the development of IDD in mice. Transcriptome analysis identified 128 common genes and eight Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for NAT. SPR-LC–MS assay detected 57 target proteins for NAT, including MAPK3 (mitogen-activated protein kinase 3), also known as ERK1 (extracellular regulated protein kinase 1). Further verification experiment confirmed that NAT significantly reduced the expression of ERK1/2 phosphorylation.

Conclusion:: NAT would induce chondrogenesis and osteogenesis of MSCs, ameliorate the secondary osteoporosis and delay the progression of IDD in mice by targeting MAPK3.Furthermore, MAPK3, especially the phosphorylation of MAPK3, would be a potential therapeutic target for IDD treatment.

Keywords

Chondrogenesis / Intervertebral Disc Degeneration (IDD) / Mesenchymal Stem Cells (MSCs) / Osteogenesis / Taurocholic Acid Sodium Salt Hydrate (NAT)

References

[1] Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Vol 396. Lancet: GBD 2019 Diseases and Injuries Collaborators; 2020. p. 1204–1222.

[2] Vedicherla S, Buckley CT. In vitro extracellular matrix accumulation of nasal and articular chondrocytes for intervertebral disc repair. Tissue Cell. 2017;49:503–513.

[3] Song Y, Lu S, Geng W, Feng X, Luo R, Li G, et al. Mitochondrial quality control in intervertebral disc degeneration. Exp Mol Med. 2021;53:1124–1133.

[4] Li G, Zhang W, Liang H, Yang C. Epigenetic regulation in intervertebral disc degeneration. Trends Mol Med. 2022;28:803–805.

[5] Xie L, Chen Z, Liu M, Huang W, Zou F, Ma X, et al. MSC-derived exosomes protect vertebral endplate chondrocytes against apoptosis and calcification via the miR-31-5p/ATF6 Axis. Mol Ther. Nucleic Acids. 2020;22:601–614.

[6] Liu Y, Li Y, Nan LP, Wang F, Zhou SF, Feng XM, et al. Insights of stem cell-based endogenous repair of intervertebral disc degeneration. World J Stem Cells. 2020;12:266–276.

[7] Liang H, Luo R, Li G, Zhang W, Song Y, Yang C. The proteolysis of ECM in intervertebral disc degeneration. Int J Mol Sci. 2022;23:23.

[8] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.

[9] Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–683.

[10] Chen Y, Sun H, Yao X, Yu Y, Tian T, Xu W, et al. Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs. Cell Mol Life Sci. 2021;78:8127–8155.

[11] Hu S, Xing H, Zhang J, Zhu Z, Yin Y, Zhang N, et al. Mesenchymal stem cell-derived extracellular vesicles: immunomodulatory effects and potential applications in intervertebral disc degeneration. Stem Cells Int. 2022;2022:7538025.

[12] Liu J, Chen J, Liu B, Yang C, Xie D, Zheng X, et al. Acellular spinal cord scaffold seeded with mesenchymal stem cells promotes long-distance axon regeneration and functional recovery in spinal cord injured rats. J Neurol Sci. 2013;325:127–136.

[13] Han B, Zhu K, Li FC, Xiao YX, Feng J, Shi ZL, et al. A simple disc degeneration model induced by percutaneous needle puncture in the rat tail. Spine. 2008;33:1925–1934.

[14] Tian Z, Ma X, Yasen M, Mauck RL, Qin L, Shofer FS, et al. Intervertebral disc degeneration in a percutaneous mouse tail injury model. Am J Phys Med Rehabil. 2018;97:170–177.

[15] Li P, Ning Y, Guo X, Wen Y, Cheng B, Ma M, et al. Integrating transcriptome-wide study and mRNA expression profiles yields novel insights into the biological mechanism of chondropathies. Arthritis Res Ther. 2019;21:194.

[16] Li P, Cheng S, Wen Y, Cheng B, Liu L, Wu X, et al. Identifying candidate genes associated with sporadic amyotrophic lateral sclerosis via integrative analysis of transcriptome-wide association study and messenger RNA expression profile. Cell Mol Neurobiol. 2023;43:327–338.

[17] Moraes DA, Sibov TT, Pavon LF, Alvim PQ, Bonadio RS, Da Silva JR, et al. A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells. Stem Cell Res Ther. 2016;7:97.

[18] Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genomics Proteomics Bioinformatics. 2021;19:578–583.

[19] Database Resources of the National Genomics Data Center. China National Center for bioinformation in 2022. Nucleic Acids Res. 2022;50:D27–D38.

[20] Kasamkattil J, Gryadunova A, Martin I, Barbero A, Schären S, Krupkova O, et al. Spheroid-based tissue engineering strategies for regeneration of the intervertebral disc. Int J Mol Sci. 2022;23:23.

[21] Anwer MS. Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology. 2004;39:581–590.

[22] Arai Y, Park H, Park S, Kim D, Baek I, Jeong L, et al. Bile acid-based dual-functional prodrug nanoparticles for bone regeneration through hydrogen peroxide scavenging and osteogenic differentiation of mesenchymal stem cells. J Control Release. 2020;328:596–607.

[23] Arai Y, Choi B, Kim BJ, Rim W, Park S, Park H, et al. Tauroursodeoxycholic acid (TUDCA) counters osteoarthritis by regulating intracellular cholesterol levels and membrane fluidity of degenerated chondrocytes. Biomater Sci. 2019;7:3178–3189.

[24] Kusaczuk M, Naumowicz M, Krętowski R, Cukierman B, Cechowska-Pasko M. Molecular and cellular effects of chemical chaperone-TUDCA on ER-stressed NHAC-kn human articular chondrocytes cultured in normoxic and hypoxic conditions. Molecules. 2021;26:878.

[25] Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, et al. A stem cell-based approach to cartilage repair. Science. 2012;336:717–721.

[26] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317.

[27] Zhang HJ, Liao HY, Bai DY, Wang ZQ, Xie XW. MAPK /ERK signaling pathway: a potential target for the treatment of intervertebral disc degeneration. Biomed Pharmacother. 2021;143:112170.

[28] Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crombrugghe B. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev. 2004;18:290–305.

[29] Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607–632.

[30] Jackson RA, Kumarasuriyar A, Nurcombe V, Cool SM. Long-term loading inhibits ERK1/2 phosphorylation and increases FGFR3 expression in MC3T3-E1 osteoblast cells. J Cell Physiol. 2006;209:894–904.

[31] Jansen JH, Weyts FA, Westbroek I, Jahr H, Chiba H, Pols HA, et al. Stretch-induced phosphorylation of ERK1/2 depends on differentiation stage of osteoblasts. J Cell Biochem. 2004;93:542–551.

[32] Gu C, Yin Z, Nie H, Liu Y, Yang J, Huang G, et al. Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1. BMC Biol. 2020;18:33.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.